CCCC FY 2022 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M-32.1% YoY

Gross Profit

$31M100.0% margin

Operating Income

-$130M-416.6% margin

Net Income

-$128M-412.2% margin

EPS (Diluted)

$-2.62

Cash Flow

Operating Cash Flow

-$106M

Free Cash Flow

-$111M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$431M

Total Liabilities

$142M

Stockholders' Equity

$289M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$46M	-32.1%
Gross Profit	$31M	$46M	-32.1%
Operating Income	-$130M	-$82M	-57.7%
Net Income	-$128M	-$84M	-52.8%